ClinicalTrials.gg
RecruitingNCT05444127SOMAWIUpdated Oct 6, 2026

Oral Health and Wilson's Disease: SOMAWI

An observational study in Wilson Disease, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 6, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.

Started
2023
with 2 others
Observational
6 of 17
5 open now
Registered
12th of 17
by date
Lead sponsor
7 of 17
Fondation Ophtalmologique Adolphe de Rothschild

Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 12th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hepatolenticular Degeneration with a site in France, or all of them as a file.
02

Study summary

Patients with Wilson disease have poorer dental and periodontal health and a have lower oral quality of life than control patients. Patients with a neurological form would also more frequently present limitations in the function of the masticatory apparatus. Systemic treatments for Wilson disease are associated with lesions of the oral mucosa. Analysis of copper level in saliva could testify to the effectiveness of copper depletion in treated patients The main objective is to compare the state of dental health between: patients with Wilson disease in the hepatic form and patients with the neurological form, and a population of controls.

Read the detailed description

The comparaison between the three groups is based on evaluation criteria wich is CAOD index of caries severity (developed by Klein and Palmer in 1940) counting the number of permanent teeth with caries (evolving to include non-cavitary caries) (C), absent due to caries (A) and filled (O) in an individual. The maximum score is 28 (third molars are not taken into account). The index is obtained from clinical examination and panoramic dental imaging.

03

Conditions studied

  • Wilson Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The recruitment of Wilson patients will be done in the coordinating center of the CRMR Wilson at the Fondation A de Rothschild Hospital. Control patients matched in age and sex will be identified among patients consulting in the oral medicine department of Charles Foix Hospital. Posters will be placed in the waiting room to inform patients of the existence of the study and promote recruitment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Express consent to participate in the study
  • Member of or beneficiary of a social security scheme
  • For cases: Affected by Wilson's disease
  • For controls: Benefiting from a first routine dental consultation with dental panoramic imaging, outside of an emergency context or treatment follow-up/maintenance

Exclusion criteria

Exclusion Criteria:

  • Patient benefiting from a legal protection measure
  • Pregnant or breastfeeding women
  • Severe psychiatric disorders with behavioral disorders
  • For cases:

    • hepatic or neurological decompensation
    • liver transplant patient
  • For witnesses:

    • Patient with hepatic or neurological disease
    • Patient taking dietary supplements enriched with copper or zinc or zinc supplementation
    • Patient wearing removable prostheses with zinc-enriched prosthetic adhesives (Fixodent ProPlus®)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cases

    patients with hepatic form of Wilson disease and those with neurological form

    Other: Saliva samples · Other: Questionnaire OHIP-14 · Other: Thorough dental examination

  • controls

    control population consulting in routine dental with panoramic dental imaging, outside of an emergency context

    Other: Questionnaire OHIP-14 · Other: Thorough dental examination

Interventions

  • OtherSaliva samples

    A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.

  • OtherQuestionnaire OHIP-14

    A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.

  • OtherThorough dental examination

    A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.

06

What researchers measure

Primary outcomes

  1. CAOD index of the severity of the caries impairment counting the number of permanent teeth decayed in an individual. The maximum score is 28 (third molars are not taken into account)

    The index is obtained from clinical examination and panoramic dental imaging

    Time frame: inclusion visit

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2023 (actual). Primary completion is estimated for Aug 2027, 51 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Oct 2026 → Aug 2027 and completion Oct 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 5, 2022
StartActual
May 17, 2023
Primary completionEst.
Aug 2027was Oct 2026
CompletionEst.
Aug 2027was Oct 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. Hopital Charles Foix is now Recruiting
Show 1 removed
  • Hôpital Charles Foix · Ivry-sur-Seine, France
Oct 6, 2026
Primary completion
Oct 2026→Aug 2027
Oct 6, 2026
Study completion
Oct 2026→Aug 2027
Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hopital Charles Foix · Ivry-sur-Seine, FranceContact added m•••@aphp.fr · •••4803
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site removed. Hopital Charles Foix is now Recruiting
    Show 1 removed
    • Hôpital Charles Foix · Ivry-sur-Seine, France
    Primary completion Oct 2026→Aug 2027
    Study completion Oct 2026→Aug 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hopital Charles Foix · Ivry-sur-Seine, FranceContact added m•••@aphp.fr · •••4803
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05444127
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
May 17, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Amélie YAVCHITZ
Contact
ayavhitz@for.paris
01 48 03 64 54
Aurélia POUJOIS
Contact
apoujois@for.paris
01 48 30 66 56
Marjolaine GOSSET
study director · Hopital Charles Foix

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion